TCRT · Alaunos Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $0 | $2.0K | - | $0 | $4.0K | $1.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $427.0K | - | $469.0K | $185.0K | $347.0K | - | $143.0K | $180.0K | $126.0K | - |
| SG&A | $585.0K | - | $718.0K | $854.0K | $747.0K | - | $1.01M | $990.0K | $1.62M | - |
| Total Operating Expenses | $1.01M | - | $1.19M | $1.04M | $1.09M | - | $1.15M | $1.17M | $1.74M | - |
| D&A | $0 | - | - | - | - | - | - | - | $2.0K | - |
| Operating Income | ($1.01M) | - | ($1.19M) | ($1.04M) | ($1.09M) | - | ($1.15M) | ($1.17M) | ($1.74M) | - |
| Interest Expense | - | - | - | - | - | - | $0 | $0 | $0 | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.01M) | - | ($1.16M) | ($1.05M) | ($1.07M) | - | ($1.13M) | ($1.13M) | ($1.68M) | - |
| EPS - Basic | ($0.59) | - | ($0.55) | ($0.63) | ($0.67) | - | ($0.70) | ($0.71) | ($1.10) | - |
| EPS - Diluted | ($0.59) | - | ($0.55) | ($0.63) | ($0.67) | - | ($0.70) | ($0.71) | ($1.10) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $354.0K | $1.39M | $1.94M | $2.88M | $319.0K | $1.09M | $1.68M | $2.46M | $4.14M | $6.06M |
| Accounts Receivable | $0 | $3.0K | $0 | $2.0K | $2.0K | $5.0K | $0 | $4.0K | $1.0K | $1.0K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $400.0K | $613.0K | $843.0K | $809.0K | $831.0K | $516.0K | $458.0K | $365.0K | $597.0K | $616.0K |
| Current Assets | $970.0K | $1.99M | $2.69M | $3.74M | $1.07M | $2.75M | $3.55M | $4.68M | $6.04M | $8.26M |
| Total Assets | $1.88M | $2.97M | $3.72M | $4.74M | $2.12M | $2.75M | $3.55M | $4.68M | $6.04M | $8.26M |
| Current Liabilities | $595.0K | $813.0K | $921.0K | $1.07M | $1.06M | $692.0K | $826.0K | $907.0K | $1.24M | $1.96M |
| Long-term Debt | - | - | - | - | - | $0 | - | - | $0 | $0 |
| Total Liabilities | $595.0K | $813.0K | $921.0K | $1.07M | $1.06M | $692.0K | $826.0K | $907.0K | $1.24M | $1.96M |
| Stockholders' Equity | $1.29M | $2.15M | $2.80M | $3.66M | $1.06M | $2.06M | $2.72M | $3.77M | $4.80M | $6.31M |
| Retained Earnings | ($925.63M) | ($924.62M) | ($923.73M) | ($922.57M) | ($921.52M) | ($920.45M) | ($919.70M) | ($918.58M) | ($917.45M) | ($915.77M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.03M) | - | - | - | ($772.0K) | - | - | - | ($1.92M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $0 | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | $0 | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($1.92M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | -54600.0% | - | - | -29150.0% | -174200.0% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -174000.0% | - |
| Net margin | - | - | - | - | -53650.0% | - | - | -28225.0% | -168200.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -191700.0% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.14 | - |
| R&D / Revenue | - | - | - | - | 17350.0% | - | - | 4500.0% | 12600.0% | - |
| SG&A / Revenue | - | - | - | - | 37350.0% | - | - | 24750.0% | 161700.0% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -53.4% | - | -31.1% | -22.2% | -50.6% | - | -31.7% | -24.1% | -27.9% | - |
| Return on equity | -78.1% | - | -41.3% | -28.7% | -101.4% | - | -41.4% | -29.9% | -35.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.63 | 2.45 | 2.92 | 3.48 | 1.00 | 3.98 | 4.30 | 5.16 | 4.87 | 4.22 |
| Quick ratio | 1.63 | 2.45 | 2.92 | 3.48 | 1.00 | 3.98 | 4.30 | 5.16 | 4.87 | 4.22 |
| Cash ratio | 0.59 | 1.70 | 2.10 | 2.68 | 0.30 | 1.58 | 2.04 | 2.72 | 3.34 | 3.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 | - | - | 0.00 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.46 | 1.38 | 1.33 | 1.29 | 2.00 | 1.34 | 1.30 | 1.24 | 1.26 | 1.31 |
| Liabilities / Assets | 0.32 | 0.27 | 0.25 | 0.23 | 0.50 | 0.25 | 0.23 | 0.19 | 0.21 | 0.24 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | 365d | - | - | 365d | 365d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.3x | - | 1.9x | 2.2x | 2.2x | - | 1.9x | 3.0x | 60.4x | - |
| P / S | - | - | - | - | 1176.9x | - | - | 2802.2x | 289826.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -100.0% | - | - | -100.0% | 100.0% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 7.3% | - | -3.2% | 10.9% | 37.3% | - | 86.7% | 85.4% | 82.0% | - |
| Net income growth (YoY) | 6.2% | - | -2.8% | 6.9% | 36.2% | - | 86.7% | 87.1% | 83.3% | - |
| EPS growth (YoY) | 11.9% | - | 21.4% | 11.3% | 39.1% | - | -1650.0% | -1675.0% | -2650.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 79.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 21.7% | 4.4% | 2.9% | -2.9% | -77.9% | -67.3% | -80.4% | -82.6% | -83.7% | -83.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$5.0K totalRoyalty$5.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Alaunos Therapeutics against the 5 most active filers in the same SIC group.